IFN-lambda therapy: Current status and future perspectives

Ahmed Lasfar, Andrew Zloza, Karine A. Cohen-Solal

Research output: Contribution to journalReview articlepeer-review

16 Scopus citations

Abstract

Interferon-lambda (IFN-λ), the most recently described type III IFN, plays a crucial part by acting on specific cell types, controlling viral infections and establishing robust innate immunity against cancer. In contrast to IFN-α or IFN-γ, IFN-λ has a restricted cell response pattern, which could make this new IFN a better choice for disease targeting and reducing adverse events. Although IFN-λ is considered to have pivotal roles in cancer, viral infections and autoimmune diseases, clinical trials have only been conducted for treatment of chronic hepatitis C virus infection. In this review, we discuss the current and the potential clinical applications of IFN-λ in the context of current IFN therapy.

Original languageEnglish (US)
Pages (from-to)167-171
Number of pages5
JournalDrug Discovery Today
Volume21
Issue number1
DOIs
StatePublished - Jan 1 2016

All Science Journal Classification (ASJC) codes

  • Drug Discovery
  • Pharmacology

Fingerprint

Dive into the research topics of 'IFN-lambda therapy: Current status and future perspectives'. Together they form a unique fingerprint.

Cite this